Endpoints News
Ionis wins rare disease approval Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
M T W Th Fri
4 September, 2026
Endpoints 11 - Reserve Your Spot - Save $100 with our Early Bird rate
One night, one room: the founders, scientists and investors behind the Endpoints 11, together in Boston this September. Reserve your spot now and save with the early bird rate.
presented by Riyadh Global Medical Biotechnology
How the Riyadh Glob­al Med­ical Biotech­nol­o­gy Sum­mit is de-risk­ing Sau­di Ara­bi­a's cell and gene ther­a­py am­bi­tions
top stories
1. Former I-Mab chief Joan Shen's NeuShen banks $80M+ for 3 brain-health drugs
2. Ionis wins FDA clearance for Alexander disease drug, company's first solo neurology approval
3. Thiel-backed Lindus pivots to hunting external drug assets after CRO-arm sale
4. Italy's Menarini gets into obesity with European rights to GLP-1 from China's Gan & Lee
5. Merck's M&A chief expects 'a lot more deal flow' as Keytruda patent cliff nears
6. Take the Q3 Biopharma Sentiment Survey (BPSI)
more stories
• 
in focus
Drew Armstrong
.

Monday is Labor Day, so Endpoints won't be publishing any newsletters. We'll be back Tuesday — enjoy the long weekend!
.
Drew Armstrong
Executive Editor, Endpoints News
@ArmstrongDrew
NeuShen CEO Joan Shen.
1
by Kyle LaHucik

A Shang­hai and Boston biotech led by a vet­er­an transpa­cif­ic drug de­vel­op­er has se­cured more than $80 mil­lion to ad­vance three clin­i­cal-stage brain-health drugs.

NeuShen...

Read the full story
The China Biotech Debate: Washington, DC from POST-HOC
Secrecy, security and policy: round two of our China biotech series lands in Washington, with the policymakers who will decide the US posture toward its biggest rival. Seats are limited. Get your ticket now.
2
by Ayisha Sharma

Io­n­is Phar­ma­ceu­ti­cals got FDA ap­proval of its rare neu­rode­gen­er­a­tive dis­ease treat­ment zil­gan­ersen, paving the way for the com­pa­ny’s first whol­ly owned neu­rol­o­gy prod­uct.

Ion­is'...

Read the full story
Endpoints webinars
Sep 10
11:00 am ET
Inside the IDMO model: Analytical comparability, regulatory readiness and operational excellence
Cellares
Sep 16
2:00 pm ET
Beyond ICD codes: Unlocking rare disease insights with genomics and claims-based data
GeneDx
Sep 22
12:00 pm ET
The future of drug pricing: Medicare negotiation, MFN models & beyond
ADVI
Oct 22
11:00 am ET
A new model for clinical research – Expanding community trial access
Parexel
3
by Kyle LaHucik

A Pe­ter Thiel-backed transat­lantic start­up that once brand­ed it­self as an “an­ti-CRO” is piv­ot­ing from a cl